Deal-Ticker: Vifor Pharma closes divestment transaction of its finished drug product manufacturing business to CordenPharma

Today, the Vifor Pharma Group closed its divestment transaction regarding its fin-ished drug product manufacturing business with facilities in Fribourg, Ettingen (both in Switzerland) and Lisbon (Portugal) to CordenPharma.

The Vifor Pharma Group is a global pharmaceutical company aiming to become the global leader in iron deficiency, nephrology and cardio-renal therapies.

Corden Pharma is a contract development & manufacturing organization of APIs, excipients, drug products and associated packaging services.

Kellerhals Carrard acted as legal advisor to Vifor Pharma on this transaction. The team was led by partner Dr. Emanuel Dettwiler and comprised senior associate Sophie Holdt, associate Jon Oetiker (all Corporate/M&A), and counsels Christine Bassanello (Employment) and Philipp d'Hondt (Notarial services).